Table 2 Association of clinical diagnosis and the immunohistochemical expression of PAX-8
PAX 8 results no. (%) | Total no. 60 | P value | ||
|---|---|---|---|---|
Positive | Negative | |||
Cancer histological type | ||||
SCC | 3 (6.7) | 42 (93.3) | 45 (75.0) | < 0.001 |
Adenocarcinoma | 11 (73.3) | 4 (26.7) | 15 (25.0) | |
Cancer site | ||||
Cervix | 8 (15.7) | 43 (84.3) | 51 (85.0) | < 0.001 |
Endometrium | 5 (100) | 0 (0.0) | 5 (8.3) | |
Ovary | 1 (25.0) | 3 (75.0) | 4 (6.7) | |
FIGO staging | ||||
Stage 1 | 1 (33.3) | 2 (66.7) | 3 (5.0) | 0.034 |
Stage 2A | 0 (0.0) | 6 (100) | 6 (10.0) | |
Stage 2B | 3 (21.4) | 11 (78.6) | 14 (23.3) | |
Stage 3A | 2 (25.0) | 6 (75.0) | 8 (13.3) | |
Stage 3B | 2 (11.8) | 15 (88.2) | 17 (28.3) | |
Stage 4A | 0 (0.0) | 3 (100) | 3 (5.0) | |
Stage 4B | 6 (66.7) | 3 (33.3) | 9 (15.0) | |
Cancer histopathological grading | ||||
Well differentiated SCC | 0 (0.0) | 12 (100) | 12 (20.0) | < 0.001 |
Poorly differentiated SCC | 2 (10.0) | 18 (90.0) | 20 (33.3) | |
Moderately differentiated SCC | 1 (7.7) | 12 (92.3) | 13 (21.7) | |
Endometrium adenocarcinoma | 9 (81.8) | 2 (18.2) | 11 (18.3) | |
Endocervical adenocarcinoma | 1 (100) | 0 (0.0) | 1 (1.7) | |
Metastatic adenocarcinoma | 0 (0.0) | 2 (100) | 2 (3.3) | |
Ovarian mucinous cyst adenocarcinoma | 1 (100) | 0 (0.0) | 1 (1.7) | |